Personalis (NASDAQ:PSNL) Reaches New 1-Year High – Here’s Why

Personalis, Inc. (NASDAQ:PSNL)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $14.83 and last traded at $14.34, with a volume of 4577511 shares traded. The stock had previously closed at $13.62.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on PSNL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Morgan Stanley cut their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Finally, BTIG Research reduced their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.00.

Personalis Price Performance

The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -14.06 and a beta of 2.24. The business’s 50-day moving average price is $9.30 and its 200 day moving average price is $8.49.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The firm had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.48 million. As a group, sell-side analysts expect that Personalis, Inc. will post -1.06 earnings per share for the current year.

Insider Activity

In related news, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the completion of the transaction, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at approximately $3,103,215.90. This trade represents a 29.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 335,032 shares of company stock worth $4,091,929. Insiders own 4.20% of the company’s stock.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd raised its holdings in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after acquiring an additional 1,479 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Personalis in the 4th quarter valued at about $31,000. Legal & General Group Plc bought a new position in shares of Personalis during the second quarter worth about $30,000. BNP Paribas Financial Markets grew its stake in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Personalis in the fourth quarter valued at about $82,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.